Santarus, Inc. : Santarus to Hold First Quarter 2012 Financial Results Conference Call on May 8
04/26/2012| 04:05am US/Eastern
Santarus, Inc. (NASDAQ: SNTS) today announced that it will release first
quarter 2012 financial results after market close on Tuesday, May 8,
2012. Santarus management will host an investment-community conference
call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the
financial results and provide a corporate update.
Individuals interested in participating in the conference call may do so
by dialing 888-803-8275 for domestic callers, or 706-643-7736 for
international callers. Those interested in listening to the conference
call live via the Internet may do so by visiting the Investor Relations
section of the company's website at www.santarus.com.
A webcast replay will be available on the Santarus website for 14 days.
A telephone replay will be available for 48 hours following the
conclusion of the call by dialing 855-859-2056 for domestic callers, or
404-537-3406 for international callers, and entering reservation code:
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company's current commercial efforts are focused on GLUMETZA®
(metformin hydrochloride extended release tablets) and CYCLOSET®
(bromocriptine mesylate) tablets, which are indicated as adjuncts to
diet and exercise to improve glycemic control in adults with type 2
diabetes, and on FENOGLIDE® (fenofibrate) tablets, which is
indicated as an adjunct to diet to reduce high cholesterol.
Santarus has a diverse product development pipeline. A New Drug
Application for UCERIS™ (budesonide) tablets for induction of remission
of mild to moderate active ulcerative colitis is under review by the FDA
with a response expected in October 2012. The pipeline also includes two
late-stage investigational drugs: RHUCIN® (recombinant human
C1 inhibitor) for treatment of acute attacks of hereditary angioedema
and rifamycin SV MMX® for treatment of travelers' diarrhea,
both of which are being evaluated in Phase III clinical studies. In
addition, the company's investigational monoclonal antibody, SAN-300, is
being evaluated in a Phase I clinical program. More information about
Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should
not be regarded as a representation by Santarus that any of its plans or
objectives will be achieved. Actual results may differ materially
from those set forth in this release due to the risks and uncertainties
inherent in Santarus' businesses, including, without limitation:
difficulties or delays in development, testing, manufacturing and
marketing of, and obtaining and maintaining regulatory approvals for,
Santarus' products; and other risks detailed in prior press releases as
well as in public periodic filings with the Securities and Exchange
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
and UCERIS™ are trademarks of Santarus, Inc.
GLUMETZA® is a trademark of Biovail
Laboratories International S.r.l. licensed exclusively in the United
States to Depomed, Inc. CYCLOSET® is a
trademark of VeroScience LLC. MMX® is a
trademark of Cosmo Technologies Limited. RHUCIN®
is a trademark of Pharming Group NV.
Martha L. Hough, 858-314-5824
& Investor Relations
Debra P. Crawford, 858-314-5708
© Business Wire 2012